Genentech's CEO Arthur Levinson will be replaced by Pascal Soriot, previously Roche's head of commercial operations for the pharma division. He will report directly to Roche's CEO Severin Schwan.
Pascal Soriot to lead Genentech
Genentech's CEO Arthur Levinson will be replaced by Pascal Soriot, previously Roche's head of commercial operations for the pharma division. He will report directly to Roche's CEO Severin Schwan.
More from Dermatological
• By
Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.
• By
Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.
• By
The Belgian firm has posted a healthy set of financials for 2024, buoyed by strong uptake in the US across all indications for Bimzelx.
• By
CEO Christophe Bourdon tells Scrip that the Danish dermatology specialist is delivering consistently strong sales while maintaining financial discipline and has created the foundation for long-term growth.
More from Therapeutic Category
• By
CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.
• By
The two companies were among those presenting data at CROI that highlighted the next frontiers of competition in the HIV space.
• By
The Swiss giant has inked a deal potentially worth $5.30bn with Zealand to access the Danish biotech's long-acting amylin analog petrelintide.